Reviewing the role of the endocannabinoid system in the pathophysiology of depression

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Gallego-Landin, Ines
• dc.contributor.author García Baos, Alba
• dc.contributor.author Castro Zavala, Adriana, 1988-
• dc.contributor.author Valverde Granados, Olga
• dc.date.accessioned 2022-02-16T07:41:25Z
• dc.date.available 2022-02-16T07:41:25Z
• dc.date.issued 2021
• dc.description.abstract Major depressive disorder is a high-impact, debilitating disease and it is currently considered the most prevalent mental illness. It is associated with disability, as well as increased morbidity and mortality. Despite its significant repercussions in our society, its exact pathophysiology remains unclear and therefore, available antidepressant treatment options are limited and, in some cases, ineffective. In the past years, research has focused on the development of a multifactorial theory of depression. Simultaneously, evidence supporting the role of the endocannabinoid system in the neurobiology of neuropsychiatric diseases has emerged. Studies have shown that the endocannabinoid system strongly impacts neurotransmission, and the neuroendocrine and neuroimmune systems, which are known to be dysfunctional in depressive patients. Accordingly, common antidepressants were shown to have a direct impact on the expression of cannabinoid receptors throughout the brain. Therefore, the relationship between the endocannabinoid system and major depressive disorder is worth consideration. Nevertheless, most studies focus on smaller pieces of what is undoubtedly a larger mosaic of interdependent processes. Therefore, the present review summarizes the existing literature regarding the role of the endocannabinoid system in depression aiming to integrate this information into a holistic picture for a better understanding of the relationship between the two.
• dc.description.sponsorship This work was supported by Ministerio de Economía y Competitividad: PID 2019-104077-RB-100/AEI/10.3389/fphar.2021.762738, Ministerio de Sanidad, Asuntos Sociales e Igualdad (Retic-ISCIII-RD/16/0017/0010-FEDER and Plan Nacional Sobre Drogas (#2018/007). AG-B received a FI-AGAUR grant from the Generalitat de Catalunya (2019FI_B0081). The Department of Experimental and Health Sciences (UPF) is a “Unidad de Excelencia María de Maeztu” funded by the AEI (CEX 2018-000792-M).
• dc.format.mimetype application/pdf
• dc.identifier.citation Gallego-Landin I, García-Baos A, Castro-Zavala A, Valverde O. Reviewing the role of the endocannabinoid system in the pathophysiology of depression. Front Pharmacol. 2021;12:762738. DOI: 10.3389/fphar.2021.762738
• dc.identifier.doi http://dx.doi.org/10.3389/fphar.2021.762738
• dc.identifier.issn 1663-9812
• dc.identifier.uri http://hdl.handle.net/10230/52503
• dc.language.iso eng
• dc.publisher Frontiers
• dc.relation.ispartof Front Pharmacol. 2021;12:762738
• dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/PID2019-104077-RB-100
• dc.rights © 2021 Gallego-Landin, García-Baos, Castro-Zavala and Valverde. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword HPA-axis
• dc.subject.keyword Endocannabinoid system
• dc.subject.keyword Major depressive disorder
• dc.subject.keyword Neurogenesis
• dc.subject.keyword Neuroinflammation
• dc.title Reviewing the role of the endocannabinoid system in the pathophysiology of depression
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion